Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Mixed Returns

Technical Trend Evolution and Price Movement

Anthem Biosciences currently trades at ₹662.05, down from the previous close of ₹686.65, marking a daily loss of 3.58%. The stock’s 52-week range spans from ₹579.45 to ₹873.25, indicating significant volatility over the past year. Today’s intraday high and low were ₹676.15 and ₹658.00 respectively, reflecting a relatively tight trading band amid broader market pressures.

The technical trend has shifted from a prolonged sideways movement to a mildly bullish pattern on the weekly timeframe. This transition is supported by the Dow Theory weekly assessment, which now signals a mild bullish trend, contrasting with the absence of a clear trend on the monthly charts. The daily moving averages, while not explicitly detailed, appear to be stabilising, suggesting potential support levels forming near current prices.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator, a key momentum oscillator, shows a mixed picture. While weekly MACD data is not explicitly quantified, the absence of a strong signal implies that the bullish momentum is tentative rather than robust. Monthly MACD similarly lacks a definitive trend, underscoring the need for investors to monitor momentum shifts closely before committing to a directional bias.

The Know Sure Thing (KST) indicator aligns with this cautious stance, showing a mildly bullish weekly signal but no clear monthly trend. This suggests that while short-term momentum may be improving, longer-term momentum remains uncertain, reflecting the stock’s recent volatility and sector-specific challenges.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on the weekly chart currently shows no definitive signal, indicating that the stock is neither overbought nor oversold. This neutral RSI reading suggests that the recent price decline has not pushed the stock into extreme territory, leaving room for either a rebound or further correction depending on broader market dynamics.

Bollinger Bands on the weekly timeframe also reflect a sideways pattern, reinforcing the notion of consolidation rather than a breakout. On the monthly scale, Bollinger Bands similarly indicate no clear directional bias, highlighting the stock’s current phase of indecision.

Volume and On-Balance Volume (OBV) Insights

Volume-based indicators provide additional context to the price action. The On-Balance Volume (OBV) metric on the weekly chart is mildly bullish, suggesting that buying pressure is gradually increasing despite recent price dips. However, the monthly OBV shows no clear trend, indicating that longer-term accumulation or distribution is not yet established.

Comparative Performance Versus Sensex

From a returns perspective, Anthem Biosciences has outperformed the Sensex over the past month and year-to-date periods. The stock posted a 9.46% gain over the last month compared to a 5.61% decline in the Sensex, and a modest 1.69% return year-to-date versus the Sensex’s 7.16% fall. However, the stock underperformed over the past week, declining 5.91% against the Sensex’s 3.84% drop.

Longer-term returns for Anthem Biosciences are not available, but the Sensex’s 10-year return of 221.00% provides a benchmark for investors assessing the stock’s potential within the broader market context.

Mojo Score and Rating Upgrade

MarketsMOJO has upgraded Anthem Biosciences’ Mojo Grade from Sell to Hold as of 04 Mar 2026, reflecting an improved outlook based on technical and fundamental factors. The current Mojo Score stands at 50.0, indicating a neutral stance. The Market Cap Grade remains low at 2, consistent with the company’s mid-cap status within the Pharmaceuticals & Biotechnology sector.

This upgrade signals a cautious but positive shift in sentiment, encouraging investors to monitor the stock for further confirmation of bullish momentum before increasing exposure.

Investor Takeaway and Outlook

Anthem Biosciences Ltd’s recent technical developments suggest a tentative shift towards bullishness, particularly on weekly charts, supported by mildly positive volume trends and a Mojo Grade upgrade. However, the absence of strong MACD and RSI signals, combined with sideways Bollinger Bands and a daily price decline, counsel prudence.

Investors should watch for confirmation of momentum through sustained price moves above key moving averages and a strengthening MACD crossover. The stock’s relative outperformance against the Sensex over the past month and year-to-date periods adds a layer of confidence, but the recent weekly underperformance highlights ongoing volatility risks.

Given the current technical and fundamental landscape, Anthem Biosciences is best approached with a Hold rating, awaiting clearer directional cues before committing to a more aggressive position. Monitoring sector trends and broader market conditions will also be critical in assessing the stock’s trajectory in the coming weeks.

Summary of Key Technical Metrics:

• Current Price: ₹662.05 (down 3.58% on day)
• 52-Week Range: ₹579.45 - ₹873.25
• Weekly Trend: Mildly Bullish (Dow Theory, OBV)
• Monthly Trend: No Clear Trend
• MACD: No strong signal weekly/monthly
• RSI: Neutral, no overbought/oversold
• Bollinger Bands: Sideways consolidation
• Mojo Score: 50.0 (Hold, upgraded from Sell)
• Market Cap Grade: 2 (Mid-cap)

In conclusion, Anthem Biosciences Ltd presents a mixed technical picture with emerging bullish signs tempered by neutral momentum indicators. Investors should maintain a balanced view, leveraging technical signals alongside fundamental analysis to navigate the stock’s evolving landscape.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →